139 related articles for article (PubMed ID: 8666122)
1. New trends in transdermal technologies: development of the skin patch, Menorest.
Marty JP
Int J Gynaecol Obstet; 1996 Mar; 52 Suppl 1():S17-20. PubMed ID: 8666122
[TBL] [Abstract][Full Text] [Related]
2. Menorest: technical development and pharmacokinetic profile.
Marty JP
Eur J Obstet Gynecol Reprod Biol; 1996 Apr; 64 Suppl():S29-33. PubMed ID: 8732471
[TBL] [Abstract][Full Text] [Related]
3. 17Beta-estradiol delivered by three different matrix patches 50 microg/day: a three way cross-over study in 21 postmenopausal women.
Rohr UD; Nauert C; Stehle B
Maturitas; 1999 Sep; 33(1):45-58. PubMed ID: 10585173
[TBL] [Abstract][Full Text] [Related]
4. Plasma estradiol concentrations and pharmacokinetics following transdermal application of Menorest 50 or Systen (Evorel) 50.
Reginster JY; Albert A; Deroisy R; Colette J; Vrijens B; Blacker C; Brion N; Caulin F; Mayolle C; Regnard A; Scholler R; Franchimont P
Maturitas; 1997 Jun; 27(2):179-86. PubMed ID: 9255753
[TBL] [Abstract][Full Text] [Related]
5. Menorest: a clinical overview.
Wren B
Int J Gynaecol Obstet; 1996 Mar; 52 Suppl 1():S27-9. PubMed ID: 8666124
[TBL] [Abstract][Full Text] [Related]
6. Comparative bioequivalence studies with Estradot and Menorest transdermal systems.
Hossain M; Quebe-Fehling E; Sergejew T; Schmidt G; Skerjanec A; Cohen A; Krinsky L; Ibarra de Palacios P
Maturitas; 2003 Nov; 46(3):187-98. PubMed ID: 14585521
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and tolerability of Menorest 50 compared with Estraderm TTS 50 in the treatment of postmenopausal symptoms. A randomized, multicenter, parallel group study.
Pornel B; Genazzani AR; Costes D; Dain MP; Lelann L; Vandepol C
Maturitas; 1995 Nov; 22(3):207-18. PubMed ID: 8746878
[TBL] [Abstract][Full Text] [Related]
8. Plasma profiles of transdermal 17 beta-estradiol delivered by two different matrix patches. A four-way cross-over study in postmenopausal women.
Rohr UD; Ehrly AM; Kuhl H
Arzneimittelforschung; 1997 Jun; 47(6):761-7. PubMed ID: 9239456
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the local tolerability and adhesion of a new matrix system (Menorest) for estradiol delivery with an established transdermal membrane system (Estraderm TTS).
Erianne JA; Winter L
Maturitas; 1997 Mar; 26(2):95-101. PubMed ID: 9089558
[TBL] [Abstract][Full Text] [Related]
10. Clinical experience with Systen, a new transdermal form of hormone replacement therapy.
Corson SL
Int J Fertil Menopausal Stud; 1993; 38 Suppl 1():36-44. PubMed ID: 8499958
[TBL] [Abstract][Full Text] [Related]
11. Estradiol pharmacokinetics after transdermal application of patches to postmenopausal women: matrix versus reservoir patches.
Reginster JY; Donazzolo Y; Brion N; Lins R
Climacteric; 2000 Sep; 3(3):168-75. PubMed ID: 11910618
[TBL] [Abstract][Full Text] [Related]
12. Clinical experience with a seven-day estradiol transdermal system for estrogen replacement therapy.
Gordon SF
Am J Obstet Gynecol; 1995 Sep; 173(3 Pt 2):998-1004. PubMed ID: 7573298
[TBL] [Abstract][Full Text] [Related]
13. Bioavailability of estradiol from two matrix transdermal delivery systems: Menorest and Climara.
Andersson TL; Stehle B; Davidsson B; Höglund P
Maturitas; 2000 Jan; 34(1):57-64. PubMed ID: 10687883
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of estradiol and of estrone during application of a new 7-day estradiol transdermal patch with active matrix.
Setnikar I; Rovati LC; Vens-Cappell B; Hilgenstock C
Arzneimittelforschung; 1998 Mar; 48(3):275-85. PubMed ID: 9553686
[TBL] [Abstract][Full Text] [Related]
15. [Kinetics of a new patch for transdermal administration of 17 beta-estradiol].
Rohr UD; Nauert C; Ehrly AM
Zentralbl Gynakol; 1995; 117(10):531-9. PubMed ID: 7491836
[TBL] [Abstract][Full Text] [Related]
16. Bioavailability Study of Menorest®, a New Estrogen Transdermal Delivery System, Compared with a Transdermal Reservoir System.
Le Roux Y; Borg ML; Sibille M; Thebault J; Renoux A; Douin MJ; Djebbar F; Dain MP
Clin Drug Investig; 1995 Sep; 10(3):172-8. PubMed ID: 27519201
[TBL] [Abstract][Full Text] [Related]
17. Drug concentration effect relationship of estradiol from two matrix transdermal delivery systems: Menorest and Climara.
Andersson TL; Stehle B; Davidsson B; Höglund P
Maturitas; 2000 Jun; 35(3):245-52. PubMed ID: 10936741
[TBL] [Abstract][Full Text] [Related]
18. Estradiol and estrone plasma levels during application of three strengths of a 7-day estradiol transdermal patch.
Setnikar I; Rovati LC; Santoro A; Guillaume M; Mignot A; Renoux A; Gualano V
Arzneimittelforschung; 1999 Aug; 49(8):708-15. PubMed ID: 10483519
[TBL] [Abstract][Full Text] [Related]
19. Plasma concentration of estradiol following transdermal administration of Systen 50 or Menorest 50.
Reginster JY; Albert A; Deroisy R; Colette J; Vrijens B; Blacker C; Brion N; Caulin F; Mayolle C; Regnard A; Sholler R; Franchimont P
Scand J Rheumatol Suppl; 1996; 103():94-8; discussion 99-100. PubMed ID: 8966499
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and tolerability of Estraderm MX, a new estradiol matrix patch.
Bacchi-Modena A; Bolis P; Campagnoli C; De Cicco F; Meschia M; Pansini F; Pisati R; Hüls G
Maturitas; 1997 Jul; 27(3):285-92. PubMed ID: 9288701
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
